Coley sets IPO price at top of range

Coley Pharmaceutical priced its IPO of 6 million shares at $16 per share, at the top of its projected range. Coley hoped to raise $97 million as shares started trading today under the COLY symbol. Under the terms of a separate agreement, Pfizer is buying 625,000 shares at $16 per share. Wellesley, Massachusetts-based Coley is developing drugs that direct the human immune system to fight cancers. A successful IPO here would be a big encouragement to the industry, which has seen biotechs taking a big discount when going public this year.

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.